What this means
This is a trial that has not reported results yet, so no findings are available. It is still recruiting people, so we do not know if the system works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 50–99
- Where
- 1 site
The science
- Registered title
- AVIGA3 (Cohort 2.0)
- Trial ID
- NCT07255859 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Maculopathy
- What is tested
- Amsler Grid, AVIGA
- Sponsor
- Tan Tock Seng Hospital
- Ages
- 50 Years to 99 Years
- Dates
- First posted Dec 1, 2025 · updated Jun 24, 2026
Registry summary
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision. It is estimated that the prevalence of early and late AMD in Asian populations aged 40 to 79 were 6.8% and 0.56% respectively. Prevalence in white populations estimated from large population studies were 8.8% and 0.59% respectively. With the aging population and people living longer, these numbers will only increase. Hence, this study aims to develop a system to evaluate the AVIGA system through remote monitoring for disease recurrence of wet aged-related macular degeneration using eye gaze tracking.
Sites (1)
- Tan Tock Seng Hospital, Singapore, Singapore